The American Medical Association Creates New Category III CPT® Codes for Interpretation and Reporting of Continuous EEG Data
- The American Medical Association creates additional CPT codes to support interpretation, reporting and remote monitoring of EEG data from a sub-scalp implantable continuous EEG monitoring system
- Epiminder, in partnership with the American Clinical Neurophysiology Society (ACNS) helped establish new codes for neurologists to utilize when reviewing continuous EEG data for their patients
MELBOURNE, AU and DALLAS, US – May 17, 2025 – Epiminder, a pioneering medical device and information solutions company, today announced, in partnership with the American Clinical Neurophysiology Society (ACNS), that the American Medical Association (AMA) has created five new Current Procedural Terminology (CPT) codes. These codes will support the reporting of services associated with interpretation and reporting of continuous EEG data along with remote monitoring services for patients with epilepsy.
The Minder® system, Epiminder’s proprietary implantable continuous EEG monitoring system (iCEM™), provides an unprecedented view into patients’ EEG data enabling more informed treatment decisions for epilepsy care. These new codes will allow qualified healthcare professionals to report services related to reviewing and interpreting their patients’ data and remotely monitor their patients to assist in ongoing epilepsy management.
Chip Moebus, Vice President of Market Access for Epiminder, said, “We appreciate the hard work of ACNS and their staff in helping create these new codes so that clinicians can better care for their patients with epilepsy. This effort continues to advance reimbursement and support for interpreting data and remote monitoring which has proven to be an important tenet in care management of other chronic conditions. The creation of these codes will complement the previously established codes used to report the implantation of continuous EEG monitoring systems, like Minder.
We’re opening the door for epileptologists to use data to better inform treatment decisions and empower them with a longitudinal view of the health of patients with epilepsy. We look forward to these codes becoming effective in January of 2026 as we start to launch the Minder system here in the United States in the second half of 2025.”
Follow Epiminder on LinkedIn and explore www.epiminder.com for more information.
About Minder
Minder is a minimally invasive device for continuous monitoring of electrographic brain activity, providing epilepsy patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities.
Minder’s long-term monitoring of patients outside of a controlled clinical environment delivers data needed for better understanding and more effective treatment of epilepsy and underlying conditions, including determining the effectiveness of drug therapies and other potential interventions.
About Epiminder
Founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent’s Hospital, the University of Melbourne and Cochlear Limited, Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders requiring continuous monitoring. Epiminder is headquartered in Melbourne, Australia and has offices in the United States.